Glenmark Pharmaceuticals has entered into an exclusive agreement with Sam Chun Dang Pharm (SCD) of South Korea to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. The ophthalmic products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorisations and commercialise the products in North America.
Company Profile : Glenmark Pharma Ltd
Leave a Reply